Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Anatara Lifesciences Ltd ( (AU:ANR) ) has issued an announcement.
Anatara Lifesciences reported a sharp 66% fall in revenue from ordinary activities to $177,564 for the half-year ended 31 December 2025. The company’s net loss after tax attributable to members narrowed by 56% to $514,975, underscoring ongoing efforts to reduce losses despite weaker top-line performance.
Net tangible asset backing per share halved to $0.004 from $0.008 a year earlier, reflecting balance sheet pressure as the company continues to fund its operations. Directors confirmed that no dividend was paid for the half-year and do not recommend a payout, indicating a continued focus on capital preservation and reinvestment over shareholder distributions.
The most recent analyst rating on (AU:ANR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Anatara Lifesciences Ltd stock, see the AU:ANR Stock Forecast page.
More about Anatara Lifesciences Ltd
Anatara Lifesciences Ltd is a life sciences company focused on developing healthcare solutions, with activities reflected through its revenue from ordinary operations. The company targets commercialising its technologies within medical and related markets, though it remains in a loss-making, development-oriented phase.
Average Trading Volume: 573,922
Technical Sentiment Signal: Sell
Current Market Cap: A$3.45M
For detailed information about ANR stock, go to TipRanks’ Stock Analysis page.